US Treasuries also declined, pushing yields on the 10-year note 3 basis points higher to 2.12 percent. Commodities weakened too.
"Hot money that flowed in, as some investors tried to trade the Fed, is now flowing out quickly," Nathan Griffiths, who manages about US$800 million in emerging-market stocks at NN Investment Partners in The Hague, told Bloomberg. "There is a very minute focus on when the Fed raises its reference rate precisely because growth fundamentals are so weak, particularly in emerging markets."
The Dow moved lower as slides in shares of Intel and those of Pfizer, last 1.8 percent and 1.7 percent weaker respectively, overshadowed gains in shares of Procter & Gamble and those of Wal-Mart, last up 0.8 percent and 0.7 percent respectively.
Shares of Pfizer fell after the company and Allergan said they were "in preliminary friendly discussions regarding a potential business combination transaction".
US-listed shares of Dublin-based Allergan jumped 7.1 percent
"It's definitely a far easier target for Pfizer than AstraZeneca," Christophe Eggmann, investment director at GAM, who holds shares in both companies, told Reuters. "It fits pretty well ... for Pfizer, so the hurdle will really be the price."
In Europe, the Stoxx 600 Index ended the day with a 0.1 percent dip from the previous close amid disappointing earnings from Deutsche Bank and Barclays. France's CAC 40 Index slipped 0.1 percent, Germany's DAX Index fell 0.3 percent, while the UK's FTSE 100 Index dropped 0.7 percent.
Meanwhile, China Premier Li Keqiang has told Communist Party members that the country needs annual growth of at least 6.53 percent in the next five years, according to Bloomberg, in order to establish a "moderately prosperous society".